A PIPELINE BUILT TO MEET PATIENTS’ NEEDS.
Our global infrastructure of ongoing trials and studies is thriving. See our work to help find new treatments for serious diseases.
Diabetes
© 2024 Corcept Therapeutics, Incorporated
Hypercortisolism (Cushing Syndrome)
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Phase IV
Endogenous Cushing syndrome (GRACE)
Relacorilant
PHASE III
Hypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)
Relacorilant
PHASE III
Extension study to evaluate long term safety
Relacorilant
PHASE II
Prevalence and treatment of Hypercortisolism (CATALYST)
Korlym
PHASE IV
Oncology
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Phase IV
Platinum-resistant ovarian cancer (ROSELLA)
Relacorilant + Abraxane (nab-paclitaxel)
PHASE III
Prostate cancer
Relacorilant + Xtandi (enzalutamide)1
PHASE II
Adrenal cancer with cortisol excess
Relacorilant
PHASE I
Neurology
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Phase IV
ALS (DAZALS)
Dazucorilant
PHASE II
Non-Alcoholic Steatohepatitis / Metabolic Dysfunction-Associated Steatohepatitis
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Phase IV
NASH (MONARCH)
Miricorilant
PHASE II
Additional Areas of Research
NASH: non-alcoholic steatohepatitis. ALS: amyotrophic lateral sclerosis. PTSD: post-traumatic stress disorder.
1 Investigator-sponsored trial, University of Chicago